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ASO Antisense oligonucleotide 
BMP Bone morphogenetic protein 
B-PEI Branched-polyethylenimine 
cm Centimeter 
CO2 Carbon dioxide 
CTAB Cetyltrimethylammonium bromid 
Da Dalton 
DNA Deoxyribonucleic acid 
DOGS Dioctadecylamidoglycylspermine 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine , 
DOTAP N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate 
DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
DMRIE 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide 
ECM Extracellular matrix 
EF Ejection fraction 
G1-phase Gap 1-phase 
G2-phase Gap 2-phase 
GAC Gene activated collagen 
GAH Gene activated human fibronectin 
GAS Gene activated substrate 
GFP Green Fluorescent Protein 
HIV Human immunodeficiency virus 
HPF High-power field 
HSC Hematopoietic stem cell 
kb Kilobase pairs 
KGF-1 Keratinocyte growth factor-1 
LMW-PEI Low molecular weight-polyethylenimine 
LNA Locked nucleic acid 
L-PEI Linear-polyethylenimine 
LV Left ventricular 
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LWT Left ventricle wall thickness 
mg Milligram 
MHz Megahertz 
MI Myocardial infarction 
MNB Magnetic nanobead 
MMP-2 Matrix metalloproteinase-2 
M-phase Mitosis-phase 
mRNA Messenger RNA 
MSC Mesenchymal stem cell 
NLS Nuclear localization signal 
nm Nanometer 
NPC Nuclear pore complexes 
N/P ratio Nitrogen/phosphorus ratio 
PAMAM Polyamidoamine 
PBS Phosphate buffered saline 
PEI Polyethylenimine 
PLL Poly-L-lysine 
PPE Polyphosphoester 
RLU Relative light unit 
RNA Ribonucleic acid 
sc Scrambled control 
SDF-1α Stromal cell-derived factor-1α 
siRNA Small interfering ribonucleic acid 
S-phase Synthesis-phase 
SV40 Simian vacuolating virus 40 or Simian virus 40 
VEGF Vascular endothelial growth factor 
W Watt 
μg Microgram 
μm Micron 
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Zusammenfassung 
 
        Gentransfer, die Technik, mit der Genmaterial in Zielzellen bzw. –gewebe 
eingebracht wird, hat über die letzten Dekaden starkes Interesse hervorgerufen. Aus 
therapeutischer Sicht handelt es sich dabei um einen vielversprechenden Ansatz zur 
Behandlung verschiedenster,  sowohl erblicher als auch erworbener Erkrankungen. In 
der wissenschaftlichen Laborarbeit wird Gentransfer als unersetzliches experimentelles 
Werkzeug bei der Erforschung von Genfunktionen angewandt. Der virale Gentransfer 
hat den Vorteil einer hohen Transduktionseffizienz, geht aber mit diversen Nachteilen 
einher: Toxizität, Immunogenität, Kanzerogenität, niedrige Zielzellspezifität, begrenzte 
Größe transfizierbarer Gene sowie hohe Kosten. Infolgedessen hat der nonvirale 
Gentransfer steigende Beachtung gefunden, da er relativ sicher ist, den Transfer großer 
Gene sowie ein spezifisches Targetting ermöglicht, weniger Toxizität und geringere 
Kosten verursacht. Von verschiedenen Verfahren zum nonviralen Gentransfers wurde 
vor allem der Polyethylenimin (PEI)-vermittelte Gentransfer intensiv erforscht und 
eingesetzt, da PEI sowohl in vitro als auch in vivo hervorragend wirkt. 
        Adulte Stammzellen sind undifferenzierte Zellen, die zur Selbsterneuerung fähig 
sowie multipotent sind. Aufgrund ihrer Fähigkeit, zu verschiedenen Zelltypen 
auszudifferenzieren, spielen Stammzellen in der Regenerativen Medizin eine 
wesentliche Rolle. Allerdings begrenzen einige Einschränkungen ihre therapeutische 
Wirksamkeit. Beispielsweise könnten Zellalterung und alterungsbedingter 
Funktionsabbau den Nutzen einer klinischen Stammzelltransplantation verringern. 
Durch die begrenzte Menge gewebeständiger Stammzellen stehen zudem nicht immer 
genug Zellen zur Verfügung, um geschädigtes Gewebe zu reparieren und zu 
regenerieren. Mit Hilfe des Gentransfers könnte diese Einschränkungen 
entgegengewirkt werden. 
        In der vorliegenden Arbeit wurden Methoden des polymervermittelten, nonviralen 
Gentransfers untersucht und in der Stammzelltherapie eingesetzt. Wir haben ein 
genaktiviertes Substrat (GAS) entwickelt, das eine lokalisierte Genapplikation sowie 
eine langanhaltende Genfreisetzung bei hoher Transfektionseffizienz und niedriger 
Zytotoxizität  ermöglicht. Das GAS könnte für gezielte Stammzellmigration und –
homing sowohl in vitro als auch in vivo eingesetzt werden und bietet so die Möglichkeit, 
Einschränkungen durch die geringe Anzahl Stammzellen in gewebeständigen 
Populationen zu überwinden. In einer unserer Studien haben wir gezeigt, dass die 
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Stammzellrekrutierung die Wiederherstellung der Herzfunktion nach Myokardinfarkt 
(MI) im Rattenmodell verbessern konnte. Dieses Ergebnis stellt eine weitere 
Bestätigung des therapeutischen Potenzials von GAS für die Geweberegeneration dar. 
Außerdem haben wir zum besseren Verständnis der Genmodifikation von Stammzellen 
die Transfektion humaner mesenchymaler Stammzellen (MSCs) durch PEI-vermittelten 
Gentransfer untersucht. Wir konnten zeigen, dass die Effizienz des Gentransfers 
unabhängig von Alter und Geschlecht des Stammzellspenders war, aber eine 
Abhängigkeit vom Zellzyklus aufwies. Als wesentliches Ergebnis zeigte sich, dass die 
Expression therapierelevanter Gene durch PEI signifikant verstärkt werden könnte, bis 
ein klinisch bedeutsames Niveau erreicht wird. Damit bietet der PEI-vermittelte 
Gentransfer die Möglichkeit, Stammzellen genetisch zu verändern und so ihre 
therapeutische Wirksamkeit zu verbessern. Außerdem konnten wir in einer weiteren 
Studie mittels einer nonviralen Methode Antisense-Oligonukleotide (ASO) 
verabreichen, so dass eine erfolgreiche Hemmung des Wachstums von Tumoren 
beobachtet wurde. 
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Summary 
 
        Gene delivery, the technique to introduce genetic materials into hosts, has drawn a 
lot of attentions in the last decades. On bed side, it is a highly promising therapeutic 
approach to treat various diseases, either inherited or acquired disorders. On bench side, 
it is an invaluable experimental tool to study gene functions. Viral gene delivery owns 
the advantage of high transduction efficiency, but it may be associated with drawbacks 
including toxicity, immunogenicity, carcinogenicity, poor target cell specificity, 
inability to transfer large size genes and high costs. As a result, non-viral gene delivery 
has attracted increasing interest since it presents relative safety, ability to transfer large 
size gene, less toxicity, site-specificity and low cost. Among various methods of non-
viral gene delivery, polyethylenimine (PEI) mediated gene transfer has been widely 
studied and utilized due to PEI’s excellent performance both in vitro and in vivo.  
        Adult stem cells are undifferentiated cells holding the properties of self-renewal 
and multipotency. Owning to their capability to differentiate into various cell types, 
stem cells have been playing an important role in regenerative medicine. However, 
some restrictions limited the therapeutic efficacy of stem cells. For example, cellular 
senescence and age-related functional decline could reduce the benefits after their 
clinical transplantation. Others include the limited tissue intrinsic stem cell pools, which 
can not provide enough stem cells to repair and regenerate damaged tissues. These 
limitations imposed on stem cell-based therapy could be addressed by gene transfer 
approach.  
        In present work, polymer mediated non-viral gene delivery technique was studied 
and utilized in stem cell-based therapy. We developed the gene activated substrate 
(GAS) which allows localized gene delivery, sustained gene release, high transfection 
efficiency and low cytotoxicity. This GAS could be used to guide stem cell migration 
and homing both in vitro and in vivo, providing the possibility to overcome the 
limitation of low stem cell amount in intrinsic tissue pools. In one of our studies, we 
have demonstrated that stem cell recruitment could improve the restoration of heart 
functions after myocardial infarction (MI) in a rat model. This result further confirmed 
the therapeutic potential of GAS in tissue regeneration. In addition, to improve our 
understanding in genetic modification of stem cells, we studied the transfection of 
human mesenchymal stem cells (MSCs) using PEI mediated gene delivery. We found 
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that the gene transfer efficiency is independent on the donors’ age and gender, but 
shows relationship with the cell cycle. Importantly, the therapeutic gene expression 
level could be significantly enhanced by PEI to a clinical meaningful level. Hence, PEI 
mediated gene delivery offers the opportunity to genetically modify stem cells and 
thereby to improve their therapeutic efficacy. Furthermore, in another study, by using 
non-viral method to deliver antisense oligonucleotide (ASO), the successful inhibition 
of tumor growth was observed. 
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Introduction 
 
1. Gene therapy 
 
         “Gene therapy” is a broad term that comprises any strategy to treat a disease by 
transferring nucleic acid materials into cells thereby regulating cellular processes and 
responses [1, 2]. Although the concept of gene therapy originally refers to the transfer of 
DNA, it currently includes the transfer of other nucleic acids materials like RNA [3], 
oligonucleotides [4] or single-stranded pieces [5].  
        Compared with traditional protein therapy, in which therapeutic proteins are given 
directly to the cells, gene therapy owns some advantages due to its capability to conquer 
the inherent problems of protein therapy such as systemic toxicity, in vivo clearance and 
high costs. The original aim of gene therapy was to treat some inherited genetic 
disorders such as cystic fibrosis [6]. Nowadays, it has been used for numerous disease 
treatment, including HIV [7], cancer [8], tissue regeneration [9] and diabetes [10] etc.  
        In gene therapy, the alternation or manipulation of genes or gene expression within 
a specific cell population of the host could be realized through the transfer of exogenous 
genetic materials, which provides the opportunities not only for clinical application but 
also for mechanism studies. Gene-related immunization can be acquired via appropriate 
gene transfer [11]. Gene transfer technique has become a powerful tool for researchers to 
identify the gene function and its regulation, thereby to establish various DNA-based 
disease models, and finally to explore potential therapeutic methods to various diseases, 
either inherited or acquired. Recently, the highly developed techniques in molecular 
biology combined with the culmination of the “Human Genome Project” have speeded 
up the understanding on cellular processes and disease pathogenesis [12, 13]. Numerous 
genes involved in diseases and cellular processes have been identified and the 
identification rate of those unclear target genes are dramatically increased with the 
usage of new techniques. All of these create promising prospects for gene therapy. 
 
1.1 Gene therapy strategies 
 
        Generally, there are two main strategies adopted in gene therapy, ex vivo and in 
vivo gene transfer (Figure 1) [14]. Ex vivo gene therapy is carried out by transfer genes 
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into the cells of interest that are previously obtained from the tissue or organs of the 
patients. The cells are cultured in vitro in appropriate culture conditions, and then 
transfected (or transduced) with the certain therapeutic genes. After transfection (or 
transduction), the cells will be transplanted back into the patient. To get enhanced 
therapeutic efficacy, the positively transfected cells can be selected out from the total 
cells for transplantation according to their ability to express the exogenous gene in a 
stable and persistent manner. In some cases, allogenic cells or even allogenic cell lines 
could be used instead of autologous cells if the organ or tissue of interest is difficult to 
extract or it is hard to culture in vitro [15]. In in vivo gene transfer, the therapeutic genes 
are delivered directly into the tissue or organs [16, 17]. The gene transfer can be performed 
either via systemic injection in which the genes are intravenously injected into blood 
stream, or via in situ injection in which the genes are injected into tissue or organs of 
interest. The successful treatment critically depends on the gene transfer efficiency and 
the expression efficiency of the gene.  
 
 
Figure1. Ex vivo and in vivo gene therapy strategies 
(Pictures are from http://www.biochem.arizona.edu/classes/bioc471/pages/Lecture25/Lecture25.html) 
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        In theory, the successfully introduced therapeutic genes have several functions in 
accordance with the treating purpose and the gene transfer methods (Figure 2): 1) 
through gene modification, the defective host gene may be partially restored by directed 
mutagenesis; 2) gene replacement may exchange the defective host gene with the 
therapeutic gene which is the normal version; 3) through gene insertion, a therapeutic 
gene may be inserted into the host genes to exert the therapeutic action; 4) the 
exogenous genes may be transferred into the nucleus without integration and may be 
expressed transiently [15].  
 
 
Figure 2. Functions of transferred genes. Gene modification, gene replacement and gene 
insertion lead to long-term gene expression, while the delivery of exogenous genes which 
temporarily stay in the nucleus induces transient expression. 
 
        Although large progresses have been made in the study of gene therapy, some 
hurdles are still standing on the way to achieve completely successful gene therapy.  
Several issues should be inevitably considered when gene therapy is applied, including 
safety, gene transfer efficiency, site-specificity and cost etc. Among these, the efficient 
transfer of therapeutic genes into the target cells is the first challenge for the researchers 
working in the field of gene therapy.  
        Today, numerous gene delivery systems and gene vectors/carriers have been 
invented and developed. They can enhance the gene transfer efficiency by different 
mechanisms, such as speeding up intracellular uptake, enhancing cells targeting, 
protecting DNA from enzymes, assisting DNA escape from lysosome and facilitating 
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DNA’s nuclear entry etc. It has become increasingly clear that the success or failure of 
gene therapy critically depends on the development of gene carriers and gene transfer 
systems or techniques [18-21].  
        In general, currently used gene transfer methods can be divided into two categories: 
viral method and non-viral method, depending on whether virus vectors are involved. 
Numerous studies about these two gene transfer methods have been done, and each of 
them presents distinct advantages and weaknesses. Viral method offers high 
transduction efficiency and long-term gene expression, but it may be associated with 
toxicity, immunogenicity, carcinogenicity, poor target cell specificity, inability to 
transfer large size genes and high costs [15, 22-24]. In contrary, non-viral method offers the 
advantages of relative safety, ability to transfer large size gene, less toxicity, site-
specificity and easiness for preparation, but it has the limitations of low transfection 
efficiency and poor transgene expression [25-28]. In short, neither of these two gene 
transfer methods is ideal, and their merits and/or shortcomings complement each other.  
 
1.2 Viral gene delivery 
 
        Viral gene delivery is performed by using viruses that can bind to the host and 
introduce their genetic material into the cells (Figure 3). The viruses must be modified 
by deleting one or several viral structural genes and introducing the therapeutic genes 
before they can be used for gene therapy. The principle of this modification is to 
remove the genetic sequences that mediate viral replication and pathogenicity, to retain 
those required for viral binding, entry and gene delivery and to construct new 
therapeutic genes [15, 19, 29]. After this modification, the viruses used as viral vectors can 
not replicate thus can not cause diseases, while they still remain the capability to deliver 
exogenous DNA into cells. Normally, viral vectors contain strong promoters to allow 
high yield of transgene expression. Viral vectors with tissue-specific promoters can 
have transduction specificity which excludes the transgene expression in other cell types 
than the target cells. Some other strategies for virus mediated targeting transduction 
include the modification of the viruses’ surface structures by specific recognition 
sequences which can allow the infection of specific cells or tissues. Nowadays, viral 
vectors falling into several categories have been studied. Each of them shows specific 
benefits and limitations, as reviewed by Boulaiz H. et al. (Table 1) [15].  
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Figure 3. Retrovirus mediated gene delivery. The genetic material in retrovirus exists in the 
form of RNA molecules, while the genetic material of the host cell exists in the form of 
DNA.  After infection of the host cell, retrovirus introduces its RNA together with some 
enzymes (reverse transcriptase and integrase) into the cell. During the process termed 
reverse transcription, the DNA copy from the RNA molecules of the retrovirus is produced 
by reverse transcriptase. After that, this DNA copy could be incorporated into the genome 
of the host cell, which is carried out by integrase. Finally, the successfully transduced gene 
will be stably expressed.  
 
 
 Retrovirus Adenovirus 
Adeno-
associated 
virus 
Herpesvirus Vaccinia virus 
Nucleic acid RNA DNA DNA DNA DNA 
Particle size 100nm 80-120nm 20-30nm 120-300nm 186nm 
Packaging capacity Up to 4-8 kb 4-8 kb Low?4 kb High?30 kb 25-75 kb 
Host range Dividing cell only 
Dividing and 
non-dividing 
cells 
Dividing and 
non-dividing 
cells 
Dividing and 
non-dividing 
cells 
Dividing and 
non-dividing 
cells 
Transgene expression 
level Moderate High Moderate Moderate Moderate 
Genome integration Yes No Yes No No 
Transgene expression 
stability Stable Transient 
Transient/Sta
ble Transient Transient 
 
Table 1. Viral vectors used for gene therapy 
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1.3 Non-viral gene delivery 
 
        Just as its name implies, non-viral gene delivery refers to any virus-free methods 
for gene transfer. DNA used in non-viral gene delivery can be delivered into cells by 
physical forces (physical methods) or by synthetic or nature compounds (chemical 
methods). Compared with viral counterparts, non-viral methods generate less toxicity 
and immunogenicity. Moreover, cell-specific gene transfer could be realized easier via 
non-viral methods, since physical delivery allows precision of spatial control and 
chemical carriers provide the opportunities to be modified by some site-specific ligands. 
Other merits of non-viral methods include low cost for production, potential for repeat 
administration and the ability to transfer DNA with large size.   
        Generally, non-viral methods show less transfection efficiency than viral methods, 
and in most cases, the transgene expression is insufficient in terms of time duration. 
However, some recent studies have indicated that gene transfer by some non-viral 
methods could achieve the transfection efficiency and expression duration on a 
clinically meaningful level. Indeed, non-viral gene delivery has already been applied in 
many clinical trails such as cancer gene therapy [30, 31] and the treatment of 
cardiovascular diseases [32].  
 
1.3.1 Barriers for non-viral gene delivery 
 
        The ideal process of non-viral gene delivery is thought to be that nucleic acid is 
rapidly delivered to the cell population of interest, is quickly uptaken by the cells, is 
subsequently transported into the appropriate cellular compartment in which the 
functionalization of the nucleic acid takes place. For this reason, several extracellular 
and intracellular barriers must be conquered to ensure the effective gene delivery. 
Epithelial, endothelial cell linings and the extracellular matrix (ECM) surrounding the 
cells compose the anatomical barriers to prevent nucleic acid macromolecules from 
accessing to the target cells directly. DNA-loaded particles administrated via blood 
circulation can be cleared by some phagocytes, such as Kupffer cells in the liver and 
residential macrophages in the spleen, before they reach the target cells. After systemic 
administration, free nucleic acid molecules without protection can be fast degraded by 
various nucleases existing in blood or ECM [33].  
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        Crossing cell membrane is regarded as the most restricting step for non-viral gene 
delivery. Normally, nucleic acids aren’t able to pass through the plasma membrane, 
because of the nature repulsion between the nucleic acids and the cell surface since both 
of them are negatively-charged. Nevertheless, some methods have been proved to 
facilitate the cellular entry of nucleic acids. Physical methods such as gene gun, 
electroporation and sonoporation can produce transient holes on cell membrane that 
allow the free entry of nucleic acids [34]. Chemical methods condense and pack nucleic 
acid molecules via chemical compounds such as cationic lipids or cationic polymers, 
thereby form complexes which present positive surface charge and could be easily 
uptaken by cells via endocytosis, pinocytosis or phagocytosis [35].   
        After cellular uptake, endosomes containing DNA will transform into digestive 
lysosomes. This transforming process consists of two steps: first is the maturation of 
endosomes from “early” to “late” stage, and second is the fusion of mature endosomes 
with lysosomes [36]. DNA in endosomes will eventually be degraded by lysosomal 
hydrolytic enzymes unless it can escape from the endosomes before the endosomes 
become mature. Currently, two endosomal escape mechanisms have been explored. 
First, pH-responsive amphipathic peptides or lipid components with acid sensitive bond 
are involved. They can disrupt the endosome membrane, and thus facilitate the 
endosomal escape [37, 38]. Second, cationic polymers such as polyethylenimine (PEI) 
were used to condense DNA and help DNA to escape from endosomes through the 
process named “proton sponge effect” [39]. PEI is only partially protonated at neutral pH, 
which allows remaining nitrogens to be further protonated at lower pH inside the 
endosomes. This will induce the influx of chloride counter ions, thereby cause osmotic 
pressure within the endosomes, and finally trigger the swelling and rupture of 
endosomes [40]. The “proton sponge effect” seems critically dependent on the nitrogens 
that are protonatable at lower pH. One evidence is poly-L-lysine (PLL). PLL has only 
primary amine groups that can not be further protonated at lower pH value, and thus 
shows less transfection efficiency than PEI. 
        After being released from endosomes into cytoplasm, DNA in free form or as 
complex has to be transported into nucleus where transcription happens. Although the 
mechanism of such transport process is still poorly understood at present, some studies 
have revealed that the complexasion by cationic lipids or cationic polymers could 
protect DNA from degradation by cytoplasmic nucleases, and thus improve the 
opportunity to enter nucleus [41]. Recently, a novel concept has been proposed, in which 
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a microtubule-directed transport mechanism was involved for intracellular transport of 
DNA-loaded nanoparticles [42].  
        Being similar to cytoplasm membrane, the nuclear envelope is another crucial 
barrier for non-viral gene delivery which prevents DNA from entering the nucleus. The 
nuclear envelope is a double-layers membrane and is interrupted by nuclear pore 
complexes (NPC) which control the transport through the nuclear envelope.  NPC has 
very small diameter (~9nm) allowing the free diffusion of molecules with small or 
medium size, but restricting the free entry of large macromolecules into the nucleus [43]. 
In nuclear transport, the uptake of large molecular proteins is an active process, which is 
mediated by nuclear localization signal (NLS) peptide through sequence-specific 
recognition [44]. The modification of gene carriers with NLS showed enhanced gene 
delivery, which is presumably due to the improved nuclear entry [45, 46]. Another 
possibility to increase the nuclear entry is to modify plasmid DNA. In one successful 
example, SV40 sequence was included into plasmid DNA and such modification led to 
increased  transgene expression, especially in non-dividing cells [47]. The SV40 
enhancer is a region known to bind to a number of general transcription factors. In 
cytoplasm, protein/DNA complexes can be formed through the binding of SV40 onto 
transcription factors; and subsequently, these complexes will enter the nucleus through 
the protein import machinery [48, 49]. Nuclear entry of DNA is largely dependent on cell 
cycle. The dissolution and reorganization of nuclear envelope during or close to mitosis 
can largely facilitate the nuclear entry of DNA molecules [50]. This has been confirmed 
by several studies, in which cells in S-phase and G2/M-phase showed significantly 
higher transfection efficiency than cells in G1-phase [51-54]. This cell cycle dependent 
property holds high potential for cancer treatment, because of the high proliferation rate 
of tumor cells.  
        In non-viral gene delivery, only very small fraction of DNA is finally delivered 
into nucleus, while most part is gathered in the perinuclear granular region [55]. The 
observation of intact polymer (e.g. PEI)/DNA complexes in the nucleus has been 
reported, indicating that the separation of DNA molecules from the polycations is not an 
indispensable procedure before nuclear entry [56, 57].   
 
1.3.2 Physical methods 
 
Microinjection 
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        Microinjection refers to the process of using a micropipette to inject solutions 
directly into a single living cell at a microscopic or borderline macroscopic level [58, 59]. 
Barber M.A. first described this technique which forms the basis for today’s 
microinjection applications [60]. Microinjection is a relative simple, economic, effective, 
reproducible and non-toxic method. Normally, a needle with the diameter around 0.5-
5μm was used to penetrate the cell membrane and/or the nuclear envelope and inject the 
genetic materials. It can be used to transfer large size DNA. However, microinjection 
requires the individual manipulation of each cell, which largely restricts the efficiency 
of performance. Other drawbacks include the low level and short duration of transgene 
expression. Microinjection can be used in vaccination procedures, in which the 
transgene expression is only required at a low level to induce an immunological 
response. 
 
Needle injection 
        The localized needle injection of naked DNA into mouse muscle was first 
demonstrated by Wolff J.A. et al. in 1990 [61]. After that, it has been applied onto 
various tissues including liver, skin, brain and tumors etc. Needle injection is thought to 
be the simplest and safest gene transfer approach by which the therapeutic genes can be 
directly injected into the tissues, organs or blood streams in a simple manner [62, 63]. 
Furthermore, not being limited by naked DNA, needle injection can be used to transfer 
RNA, DNA/cationic polymer (or cationic lipid) complex and oligonucleotide. Some 
other injectable agents can been involved into this procedure to enhance the gene 
expression, such as transferrin, water-immiscible, solvents, nonionic polymers, 
surfactants or nuclease inhibitors [64-67]. Owning to these merits, this gene transfer 
procedure is particularly attractive for the clinical applications. A lot of efforts have 
been made in cancer gene therapy using this approach [68-70]. Injection of vascular 
endothelial growth factor-2 (VEGF-2) gene into patients suffering chronic myocardial 
ischemia has shown some positive therapeutic effects including the improvement of 
heart function.  [71]. Today, direct injection of genes into muscle or skin has become a 
very convenient and useful tool to evaluate DNA-based vaccination [33]. The 
disadvantages of needle injection include the poor level of transgene expression, 
especially when naked plasmid DNA was injected since unprotected DNA will be 
rapidly degraded by the nucleases.  
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Jet injection 
        Compared with conventional needle injection, jet injection is a needle-free gene 
delivery method that was first described in 1947 [72]. In jet injection, DNA solution is 
driven by pressurized gas, usually CO2, to form high-speed and ultrafine stream. 
Generally, the procedure of jet injection consists of several steps: DNA loading, gas 
pressure adjustment and injection. The high-speed DNA stream hitting the target cells 
generats pores on cell membrane. The intracellular entry of DNA can be largely 
facilitated by these pores. In jet injection, the mechanical properties of the target cells 
should always be considered, and the gas pressure should be adjusted to fit the cells. 
Ren S. et al. reported that transgene expression by jet injection could be improved 
around 50-folds compared with needle injection [73]. Jet injection can be used to transfer 
genes into various types of cells or tissues, such as muscle, skin and fat. It has shown 
high potential for cancer inhibition [74, 75]. Most importantly, no serious side effects were 
reported until now except for local pain, edema and site-bleeding [76].  
 
Gene gun 
        Gene gun, also known as Ballistic DNA injection or DNA-coated particle 
bombardment, was originally designed for plant transformation. Today, this technique 
has been widely used as a gene delivery approach owning to its numerous merits. It has 
been applied on various tissues or cells including skin, mucosa, muscle, tumors and 
some surgically exposed tissues [77, 78].  The particles used as payload are heavy metals, 
usually gold, tungsten or silver. These particles are first coated with plasmid DNA, then 
are accelerated by electric discharge or gas jet to a certain speed, and finally fired at the 
target cells or tissues. The momentum of the particles can lead to the penetration into 
the tissues around a few millimeters deep, and thereby the loaded DNA can be released 
into cells on the path of the particles [79]. Particle speed, particle size and dosing 
frequency are crucial parameters that influence the particle penetration, the tissue injury 
degree and the gene transfer efficiency [80]. As a simple and effective approach for gene 
delivery, gene gun has extensively been tested for intramuscular, intradermal, and 
intratumor genetic immunization. It was reported that gene gun can induce more 
immune response with lower doses than needle injection in large animal models and 
clinical human trials [33]. Further improvement of this approach could be made from the 
following aspects: 1) modification of the particles’ surface to allow higher DNA loading 
capacity, 2) precise control of particles flying and DNA release, 3) the shortening of 
Polymer mediated gene delivery for adult stem cell therapy 
Introduction- gene therapy 11 
operation time duration, and 4) reduced tissue damage without decreasing gene transfer 
efficiency.  
 
Electroporation 
        Gene delivery by electroporation employs high-voltage electrical currents to create 
transient nanometric pores on cell membrane, thus allowing negatively-charged DNA to 
move intracellularly and to remain trapped within the cells. The first utilization of 
electroporation for in vitro and in vivo gene transfer was reported in 1982 [81] and 1991 
[82], respectively. Until now, numerous works have been done for deeper study on 
electroporation including the in vitro optimization [83] and in vivo test in different types 
of tissues [81, 84]. Hasson E. et al. found that electroporation could significantly enhance 
the transgene expression in lung cells which were cultured ex vivo [85]; Dean D.A. et al. 
reported the application of this technique in living animals by placing electrodes into the 
chest [86]; Magin-Lachmann C. et al. successfully transfered large size DNA (100kb) 
into muscle cells [87]; Molnar M.J. et al. observed that gene expression lasts over 1 year 
in mouse muscle after gene transfer via electroporation [88]; and Marti G. et al. studied in 
vivo electroporation to improve wound healing in a diabetic mouse model by 
transferring keratinocyte growth factor-1 (KGF-1) [89]. Excitingly, localized gene 
transfer by electroporation was reported by Sakai M. et al. [90]. In their study, systemic 
plasmid DNA injection through the portal vein followed by a localized electroporation 
on rat liver resulted in widespread gene expression in hepatocytes in the treated lobe but 
not in the surrounding lobes. This indicates the possibility that DNA can be 
administrated via blood circulation and then be locally delivered in defined tissue via 
electroporation. The gene transfer efficiency of electroporation is influenced by several 
factors including the electrical current intensity, time interval between discharges, 
concentration and type of DNA. It was also reported that the age of the recipient 
animals [91] and the distribution of plasmid DNA in the tissue [92] could influence 
transfection efficiency. Electroporation is relatively safe, efficient and reproduceable. 
Generally, it can be applied to all cell types. With optimized parameters, electroporation 
could achieve high transfection efficiency being similar to viral method [93]. 
Nevertheless, some drawbacks of this approach still exist, especially for in vivo 
application. The limited range between the electrodes (~1cm) restricts the gene transfer 
to large area of tissues. Furthermore, a surgical procedure is required for in vivo 
electroporation to put the electrodes into the organs. Moreover, high voltage applied to 
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cells might induce tissue damage and probably influence the stability of genomic DNA 
[94, 95]. However, some of the concerns may be resolved by further technical 
development including new design of the electrodes and optimization of the operating 
parameters (e.g. the frequency and duration of electric pulses).  
 
Sonoporation 
        Sonoporation, also called ultrasound-facilitated gene transfer, as the term indicated, 
is a technique that uses ultrasound waves to induce cell membrane permeabilisation and 
thereby realize gene transfer. It was first described in 1954 by which the transdermal 
penetration of drugs was enhanced by ultrasound [96]. Currently, ultrasound has been 
used for gene transfer in cellular [97] and tissue levels [98], expanding the methodology of 
physical gene transfer methods. Several critical parameters determine the transfection 
efficiency of sonoporation, including the ultrasound frequency, the ultrasound intensity, 
the duration of the ultrasound applied, the amount of plasmid DNA used and the tissue 
type. Normally, ultrasound with frequency 1-3MHz and intensity 0.5-2.5W/cm2 was 
selected for gene delivery studies [97]. With the facilitation of ultrasound, a significant 
enhancement (10-20 folds) of reporter gene expression could be achieved over that of 
naked DNA [79]. The use of contrast agents or some conditions that make cell membrane 
more fluidic can largely enhance the gene transfer efficiency [99-101]. The contrast agents 
are normally air-filled microbubbles stabilized by surface active molecules such as 
albumin, polymers or phospholipids. These microbubbles expand and shrink rapidly 
under ultrasound irritation, releasing local shock waves that transiently disrupt the 
membrane of nearby cells and consequently facilitate local gene transfer. The utilization 
of complexes composed of DNA/cationic lipids or polymers could further improve the 
gene transfer efficiency, which has been studied both in vitro and in vivo [102, 103]. 
Sonoporation shows the advantages of safety, noninvasiveness and the ability to transfer 
genes into internal organs without surgical operations [104-107]. Interestingly, recent study 
demonstrated that ultrasound could enhance the permeability of blood-brain barrier [108]. 
However, like other non-viral methods, the gene transfer efficiency of sonoporation 
needs to be further improved. 
 
Hydrodynamic gene transfer 
        Hydrodynamic gene transfer can deliver genes into highly perfused internal organs. 
When a large volume of DNA solution is rapidly injected into mouse tail vein, 
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transgene expression can be observed in liver, lung, kidney, spleen and heart. It was 
reported that an injection of 5μg of plasmid DNA could finally generate around 45μg 
luciferase protein per gram liver tissue, and approximately 30-40% of hepatocytes could 
be transfected [109, 110]. The high pressure is the DNA driving force. When the large 
volume of DNA solution (more than 8% of body weight) is injected quickly (around 5 
seconds or less) into the tail vein, a transient overflow of injected solution will happen 
at the inferior vena cava exceeding the cardiac output. As a result, a reversible 
permeability change in the endothelial lining will be induced and some transient pores 
in hepatocyte membrane will be generated, which facilitates the entry and expression of 
DNA [111]. 
        Hydrodynamic gene transfer has been used in many rodent models to transfer 
therapeutic genes including hemophilia factors [112, 113], alpha-1 antitrypsin [109, 114, 115], 
cytokines [116], hepatic growth factors [117] and erythropoietin [118] etc. Importantly, this 
approach can deliver not only genes but also other water soluble compounds like small 
dye molecules, proteins, oligonucleotides and siRNAs etc [119]. The delivery efficiency 
is highly dependent on organ type, injection volume, injection speed and the total 
amount (or concentration) of the functional substance. At present, hydrodynamic gene 
transfer can not be applied in human clinical trials because of the injection volume. 
Mouse or rat can be treated with an injection volume equivalent to 8% of its body 
weight, which would be far beyond the acceptable level if the same ratio of injection 
volume was applied to human. However, by using a catheter-based technique, 
hydrodynamic gene transfer into the liver of pigs has been carried out with reduced liver 
damage [120-122]. The development of new technologies, such as computer-controlled 
delivery systems, could evolves this method for further utilization in clinical 
applications [123]. 
 
Mechanical massage 
        This method was reported by Liu F. et al. [124]. Their result showed that significant 
gene expression in the liver of mice could be achieved via simple mechanical massage 
after intravenous injection of naked plasmid DNA. It is believed that mechanical 
massage can generate transient disruption on the membrane of liver cells, which allows 
the entry of plasmid DNA by diffusion. They also found that the level of liver gene 
expression is significantly related with the venous blood pressure, suggesting that liver 
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gene transfer by mechanical massage is, at least in part, due to pressure-mediated effect 
[125].  
 
1.3.3 Chemical methods 
 
        In recent years, chemical non-viral vectors, such as calcium phosphate, 
diethylaminoethyl-dextran, cationic lipids and cationic polymers, have been widely 
studied due to their advantages including safety, large size gene transfer capability, less 
toxicity and easiness for preparation etc [15]. Among these, cationic lipids and cationic 
polymers show prospects to be promising gene carriers by forming condensed 
complexes with negatively-charged DNA through electrostatic interactions. The 
condensed complexes with positive net charge can be taken up by cells via endocytosis. 
Polymers or lipids can facilitate endosomal gene escape and protect DNA from 
degradation by nuclease. Finally, a small fraction of DNA can be released into 
cytoplasm and migrate into the nucleus where transgene expression takes place [79, 126].  
 
Cationic lipids (liposomes) 
        The first utilization of cationic lipid was reported in 1987 by Felgner P.L. et al. 
who used a double chain monovalent quaternary ammonium lipid, N-[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), to condense and 
transfer DNA into cultured cells [127]. After that, numerous cationic lipids have been 
developed and studied [128-132].  
        All cationic lipids are composed of three parts: hydrophilic head group, linker and 
hydrophobic anchor (Figure 4) [133]. The hydrophilic heads normally employ one or 
more positively-charged amine groups as the cationic moiety. According to the charge 
number on the hydrophilic head, cationic lipid can be classified as monovalent and 
multivalent. The hydrophobic anchors are nonpolar hydrocarbon moieties of the 
cationic lipids. They can be grouped into several categories according to the chemical 
structure: single chain hydrocarbons [134], double-chain hydrocarbons [135], cholesterol 
[136] and vitamin D-based [137]. The linker is a chemical part connecting the hydrophilic 
head group and the hydrophobic anchor. The linkers also play very important role in 
cationic lipid mediated gene delivery because their properties determine the 
biodegradability of cationic lipids and influence the toxicity and gene transfer efficiency 
[138, 139].  
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Figure 4. Structure of some cationic lipids and neutral lipids (co-lipids) commonly used in 
gene therapy. 
 
        Cationic lipids can be used alone or together with co-lipids. 1,2-dioleoyl-sn-
glycero-3-phosphatidylethanolamine (DOPE), one of the most commonly used co-lipids, 
led to the improvement of gene transfer efficiency when mixed with some cationic 
lipids, such as DOTMA and DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
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trimethylammonium methylsulfate) [140-142]. This effect of DOPE was due to its 
capability to facilitate the lipoplex forming and its tendency to transit lipoplex from a 
bilayer to a hexagonal structure under acidic pH at endosomal level, which may 
facilitate the fusion or destabilization of endosomal membranes [143-146]. Further studies 
also found that DOPE could facilitate the DNA release from lipoplex and the DNA 
escape from endocytotic vesicles [147, 148]. Cholesterol is another commonly used co-
lipid. Compared with DOPE, cholesterol could form more stable but less efficient 
lipoplex. This is meaningful for in vivo gene delivery since cholesterol could stabilize 
the lipoplex against the destructive effects of serum, and thus provide better biological 
activity than DOPE [149-153].  
        The lipoplexes can be prepared by mixing diluted plasmid DNA solution and 
cationic liposomes. Several lipoplex structures have been reported including the 
“spaghetti-meatball”, “sandwich”, “honeycomb” and “invaginated bilayer” etc [144, 154-
156]. The transfection efficiency of lipoplexes was influenced by several factors, 
including the structure and property of cationic lipid, the lipoplex size [157-159], the 
charge ratio between the cationic lipid and DNA [160, 161], the applied lipoplex amount, 
the structure and proportion of co-lipid [162-164], the cell type [165] and the cell cycle [166].  
        In summary, as non-viral gene delivery vectors, cationic lipids show advantages of 
being inexpensive and easy to prepare. They can also be modified for targeted gene 
delivery. However, two main shortcomings of cationic lipids still need to be solved, i.e. 
the toxicity and relative low transfection efficiency, to extend their applications 
especially for in vivo treatment.   
 
Cationic polymers 
        Cationic polymers are used as gene carriers since they can largely improve gene 
transfer efficiency. Generally, cationic polymers possess amine groups at a high density. 
These amine groups are protonatable at neutral pH and form positively-charged polymer 
molecules. When cationic polymers are mixed with negatively-charged DNA, 
polymer/DNA complexes (polyplexes) are generated through the electrostatic 
interaction. Polyplexes are the transfection units having the nanoscale particle size 
(normally form dozens to hundreds of nanometers). It’s believed that two mechanisms 
contribute to the improvement of gene transfer efficiency in cationic polymer mediated 
gene delivery. First, polymer can enhance the polyplex uptake via endocytosis because 
there are charge-charge interactions between polyplexes and the anionic sites on cell 
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surface. Second, polymer can protect DNA from nuclease degradation and facilitate 
DNA’s endosomal escape (Figure 5).  
 
 
Figure 5. Cationic polymer mediated gene delivery. 
 
        In the past years, a large number of cationic polymers have been developed and 
studied (Figure 6). These include: 1) natural polymers such as chitosan [167, 168], 2) 
dendrimers such as polyamidoamine (PAMAM) [169], 3) polypeptide such as PLL [170], 
polyarginine [171], polyornithine [172, 173], histones [174] and protamines [175] and 4) other 
polymers such as PEI [176, 177] and polyphosphoester (PPE) [178], etc. Additionally, some 
of them have been modified to improve the functions, such as increasing transfection 
activity or reducing toxicity. As a result, some polymers have a large number of 
derivatives. However, with the usage of different polymers, the transfection activity and 
toxicity might vary dramatically. 
        Among numerous cationic polymers, PEI has been considered as the most effective 
one. PEI can be synthesized via acid-catalyzed ring opening polymerization of aziridine 
as either branched or linear structure, or via hydrolysis of poly(2-ethyl-2-oxazolium) as 
linear structure. Branched-PEI (B-PEI) contains primary, secondary and tertiary amine 
groups, while linear-PEI (L-PEI) mostly has secondary amines except the primary 
amines of the terminal ends. PEI is capable to condense DNA molecules to form 
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PEI/DNA complexes. These complexes are homogeneous spherical particles that can be 
uptaken by cells via endocytosis [179, 180]. Intracellularly, PEI’s higher charge density can 
provide protection for DNA against nuclease degradation, and can facilitate DNA’s 
endosomal release through “proton sponge effect” [39].  
 
 
Figure 6. Structure of some cationic polymers commonly used in gene therapy. 
 
        The performance of PEI in gene delivery is critically determined by its molecular 
weight. With the increase of PEI’s molecular weight, the gene transfer efficiency is 
increased, whereas the cytotoxicity is also improved [181]. Hence, the balance between 
the efficiency and toxicity is the most important point for PEI mediated gene delivery. 
Currently, 25kDa (molecular weight 25,000 Dalton) B-PEI and 22kDa L-PEI are the 
most commonly used PEI polymers. Both of them lead to efficient gene transfer 
efficiency and induce moderate cytotoxicity [182, 183]. L-PEI leads to faster gene 
expression than B-PEI, perhaps due to the weaker DNA condensing capability of L-PEI 
that allows faster polymer/DNA dissociation in the cells. In vivo study has shown 
promising result, in which L-PEI was used for intravenous gene delivery into mouse 
lung [184]. Furthermore, L-PEI has been shown to mediate a cell cycle independent gene 
delivery [52], providing an option to deliver genes into slow-dividing cells.  
        In our work, 25kDa B-PEI mediated gene delivery into bone marrow derived 
human mesenchymal stem cells (MSCs) was studied [Attached article 1]. Our results indicated 
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that PEI has the potential to become a clinical meaningful non-viral gene vector, though 
further improvement is still necessary to enhance its gene delivery performance. In 
another study, we investigated a gene activated substrate (GAS) mediated non-viral 
gene delivery [Attached article 4&5]. GAS solution was prepared by mixing substrate materials 
(rat tail collagen or human fibronectin) with 25kDa B-PEI/DNA complexes. The GAS 
solution could be easily coated onto cell culture dish or the surface of scaffold materials. 
After the drying of GAS, the cells could be cultured on it and be transfected 
subsequently (Figure 7). Compared with normal transfection, in which polyplexes were 
added directly into cell culture medium, GAS mediated gene delivery could lead to 
lower cytotoxicity, sustained gene release, localized gene delivery and relative high 
transfection efficiency. In addition, such GAS could be easily coated onto scaffold 
materials for implantation, and in vivo transgene expression has been observed.    
 
 
Figure 7. Principle of in vitro transfection via normal method and GAS mediated method. 
In normal transfection, polyplexes were added directly into cell culture medium. In GAS 
mediated transfection, the procedure consists of several steps: 1) the polyplexes were mixed 
together with substrate materials; 2) the GAS mixture was coated onto cell culture dish; 3) 
after drying of GAS, cells were cultured onto it; 4) sustained gene release and transfection 
were achieved in the following days.  
 
        Recently, some strategies to prepare novel polymers based on low molecular 
weight-PEI (LMW-PEI), such as PEI800 (molecular weight 800Da) and PEI1800 
(molecular weight 1800Da), have been developed. LMW-PEI could be crosslinked via 
some crosslinking reagents or inert polymers. After such crosslinking, the new polymers 
present the advantages of both high and low molecular weight-PEIs, i.e. high 
transfection efficiency and low cytotoxicity. Meaningfully, biodegradable polymers are 
available if biodegradable crosslinking bonds or biodegradable polymers are involved 
[185-188]. Since the main drawback of high molecular weight PEI is the non-
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biodegradability, biodegradable crosslinking will largely extend the application of PEI-
based gene delivery especially for in vivo treatment. 
        Despite the achieved progress, cationic polymers need to be further studied to 
improve their performance. Potential strategies include: 1) modification or conjugation 
by other polymers, targeting ligands or nuclear localization signals, 2) combination with 
other gene carriers such as liposomes and inorganic materials, and 3) synthesis of novel 
polymers.   
 
Inorganic nanoparticles 
        Inorganic nanoparticles show potential to become gene carriers since they can be 
loaded with nucleic acids via absorption or conjugation, and the loaded nucleic acids 
can be transfered into living cells when these nanoparticles are uptaken by cells. 
Compared with organic nanoparticles, inorganic nanoparticles hold some advantages, 
such as high stability, low cytotoxicity and easiness for preparation. Numerous 
inorganic nanoparticles have been studied for gene delivery, including calcium 
phosphate [189], carbon nanotubes [190], magnetic nanobeads [191], silica [192], gold [193], 
quantum dots [194], and double hydroxide [195] etc. Some of them showed high promising 
performance. For example, by conjugating DNA onto supraparamagnetic nanoparticles, 
“magnetic force guided” gene delivery was realized both in vitro and in vivo [196, 197]. By 
immobilizing plasmid DNA onto the nickel-embedded carbon nanotubes and applying a 
magnetic driving force, an unprecedented high transfection efficiency was achieved [198].  
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2. Stem cell therapy 
 
        Adult stem cells, also known as somatic stem cells, are undifferentiated cells 
holding the properties of self-renewal and multipotency. They are found throughout the 
body after embryonic development, that can replenish dying cells and regenerate 
damaged tissues through multiplication via cell division. The ability to generate the 
cells of the organ from which they originate makes adult stem cells attract scientific 
interest. More importantly, unlike embryonic stem cells, the use of adult stem cells in 
research and therapy does not induce ethical controversy since they are derived from 
adult tissues. 
 
2.1 Mesenchymal stem cell 
 
        Mesenchymal stem cell (MSC) is an important cell type of adult stem cells. MSCs 
are multipotent and can differentiate into a variety of cell types, such as adipocytes, 
chondrocytes, muscles, osteocytes and stromal cells (Figure 8) [199, 200]. The first 
identification of MSCs was done about 30 years ago by Friedenstein A.J. et al. Since 
then MSCs have been isolated from bone marrow due to their ability to adhere to cell 
culture plastics [199]. Beside bone marrow, MSCs can be isolated from various other 
tissues including peripheral blood [201], periosteum [202, 203], umbilical cord blood [204], 
synovial membrane[205], pericytes [206], trabecular bone [207, 208], adipose tissue [209, 210], 
limbal stroma [211], amniotic fluid [212], lung [213], dermis [214] and muscle [215]. Currently, 
bone marrow aspiration is considered to be one of the most accessible and enriched 
sources of MSCs. Multipotent cells existing in bone marrow can gain access to various 
tissues via the circulation, subsequently start differentiation according to the 
requirements of maintenance and repair of a certain tissue type.  
        Due to the multipotency to differentiate into a various cell types, human MSCs 
have been a promising candidate for clinical use. The use of human MSCs in clinical 
applications requires the biological understandings of MSCs. Currently, the MSCs-
based bench works focus on several aspects including the identification of MSCs, the ex 
vivo expansion, the senescence, the control of differentiation potential and the delivery 
method. The bedside application of MSCs in clinical therapy could be performed in 
several ways: local transplantation, systemic transplantation and combination with 
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tissue engineering. Some clinical case reports have demonstrated the use of MSCs in the 
treatment of bone defects [216], cartilage defects [217], myocardial infarction (MI) [218], 
chronic skin wounds [219], osteogenesis imperfecta in children [220], graft-versus-host 
disease [221], Hurler syndrome [222] and tissue reconstruction [223]. Recent study further 
indicated that MSCs can support unrelated donor hematopoietic stem cells and regulate 
immune response [224].  
 
 
 
Figure 8. Models of MSC differentiation. 
 
2.2 Hematopoietic stem cell 
 
        Hematopoietic stem cell (HSC) is a type of multipotent adult stem cells that are the 
source of all blood cell lineages, including myeloid (monocytes and macrophages, 
neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic 
cells), and lymphoid lineages (T-cells, B-cells, NK-cells) (Figure 9)[225, 226]. HSCs 
transplantations are most often performed for people with diseases of the blood, bone 
Polymer mediated gene delivery for adult stem cell therapy 
Introduction- stem cell therapy 23 
marrow, or certain cancer. HSCs-based therapeutics have been applied for kidney repair 
[227], liver repair [228], multiple sclerosis treatment [229], beta-thalassemia treatment [230] 
and multiple myeloma remission [231] etc. 
 
 
 
Figure 9. Models of HSC differentiation. 
 
        In our study, the therapeutic effect of stem cells on the restoration of heart 
functions after MI in a rat model was studied [Attached article 2]. Following acute MI, 
Matrigel was delivered into myocardium by intracardiac injection. We found that the 
left ventricular (LV) function, the infarct wall thickness of left ventricle and the 
capillary density of the Matrigel treated hearts were significantly improved, compared 
with the control group (PBS treated hearts). In addition, the number of CD34+ and 
CD117+ stem cells was found to be significantly more in the Matrigel treated hearts than 
in the PBS treated hearts. Thus, we assumed that the restoration of myocardial functions 
may partly attribute to the improved recruitment of CD34+ and CD117+ stem cells. 
Polymer mediated gene delivery for adult stem cell therapy 
Introduction- application of gene delivery in stem cell therapy 24 
3. Application of gene delivery in stem cell therapy 
 
        Genetic modification of stem cells is an attractive approach for stem cell therapy 
because stem cells have higher proliferative capacity and long-term survival compared 
with other somatic cells. Genetically modified stem cells can deliver certain genes or 
proteins into organs or tissues according to specific requirements.  
        By genetic modification, stem cells could be guided to directed and complete 
differentiation towards the desired lineages. The fate of transplanted stem cells in vivo 
mainly depends on the microenvironment they home. However, not all transplanted 
cells differentiate into the desired lineages to help the repair of the damaged tissue. 
Recent study has indicated the potential risk of transplanted MSCs that differentiated 
into osteoblastes in the heart [232]. Thus, to guide the differentiation of stem cells by 
genetic modification with key differentiation factors seems crucial for stem cell therapy. 
Some studies based on animal models have shown that MSCs transduced with BMP2 
and BMP4 could repair articular cartilage and bone defects since BMPs have the ability 
to induce chondrogenic and osteogenic differentiation [233-236]. More importantly, the 
genetically modified stem cells not only themselves undergo differentiation but also 
stimulate the neighbouring cells to participate in the repair process [200]. Furthermore, 
the therapeutic efficacy of stem cells could be improved via genetic modification. As 
we know, the clinical benefits of adult stem cells after transplantation are normally 
limited by the poor quality of the cells, such as cellular senescence and age-related 
functional decline [237, 238]. Genetic modification is thought to be an effective approach 
to reduce these limitations imposed on adult stem cells.  
        Some genetic disorders could be also treated with genetically modified stem cells. 
Human MSCs transfected with dystrophin could complement Duchenne muscular 
dystrophy myotubes via cellular fusion [239]. Chamberlain B.R. et al. disrupted 
dominant-negative mutant COL1A1 collagen genes in MSCs from osteogenesis 
imperfecta patients, demonstrating successful gene targeting in adult human stem cells 
[240]. Other utilizations of gene delivery in stem cell research include the genetic labeling 
of the cells for in vitro or in vivo tracking. GFP is one of the most commonly used 
labeling genes which provides the convenience to study stem cell fate.  
        In our study, aimed on the improvement of understanding in polycation mediated 
gene delivery into adult stem cells, we used 25kDa B-PEI to deliver genes into bone 
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marrow derived human MSCs [Attached article 1]. The MSCs were donated by patients aged 
from 41 to 85 years old suffering cardiovascular disease. The gene delivery conditions 
were optimized in term of nitrogen/phosphorus ratio (N/P ratio) of PEI/DNA, PEI/DNA 
complex size and surface charge, DNA dosage, cell viability and transfection efficiency. 
The highest transfection efficiency was achieved at N/P ratio 2 and 6.0μg DNA/cm2 
culture area, while the cell viability under this condition was still at a high level (near 
60%). We didn’t observe the influence of age and gender of the patients on the 
transfection efficiency. The average transfection efficiency for cells of totality, middle-
age group (donor age<65y), old-age group (donor age>65y), female group and male 
group was 4.32%, 3.85%, 4.52%, 4.14% and 4.38% respectively, as evaluated by flow 
cytometry. Interestingly, two subpopulations in the donors were observed; and in each, 
the transfection efficiency was linearly correlated to the cell percentage in S-phase. 
However, phenotypic characterization based on stem cell markers (CD29, CD44, CD45, 
CD73 and CD105) showed no significant differences between these two subpopulations. 
Finally, the transfer of therapeutic gene was studied using human VEGF165 plasmid. 
Result indicated that VEGF expression could be significantly enhanced by PEI to a 
clinical meaningful level.  
        Gene delivery could be also used for stem cells recruitment, in which stem cells are 
not transfected but attracted by signaling proteins (e.g. cytokine) expressed by other 
transfected cells. Although various tissue intrinsic stem cells have the capabilities of 
maintaining, generating and replacing, the limited stem cell pools are not sufficient to 
repair and regenerate damaged tissues [241]. Local delivery of chemotactic factors to 
recruit the stem cells from other tissues has been thought to be a promising therapeutic 
strategy to overcome this limitation in tissue regeneration [242]. In our study, plasmid 
DNA encoding stromal cell-derived factor-1α (SDF-1α) was delivered into cells via 
GAS mediated non-viral method [Attached article 4&5]. The expression of SDF-1α induced 
CD117+ migration and homing both in vitro and in vivo. SDF-1α is a pivotal chemokine 
being able to guide stem cells to damaged tissues or organs [243]. Tissue repairs and 
functional improvements have been observed through SDF-1α mediated stem cells 
homing in many studies [244-250]. However, SDF-1α has very short half-life which is less 
then 15 minutes. It could be inactivated and cleaved by matrix metalloproteinase-2 
(MMP-2) and CD26/dipeptidyl peptidase IV, which are abundant under inflammatory 
conditions [251-253]. In situ delivery of DNA encoding SDF-1α could lead to sustained 
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SDF-1α expression, and thereby improve the efficacy to recruit stem cells to the injured 
sites.  
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Results 
 
1. PEI mediated genetic modification of human bone marrow 
MSCs 
 
        Genetic modification of stem cells is an effective approach to improve the efficacy 
of stem cell-based therapy. In our study, PEI mediated gene delivery into human bone 
marrow MSCs from patients was investigated [Attached article 1]. 
        At N/P ratio 2 and 6.0μg DNA/cm2 culture area, MSCs showed optimal 
transfection efficiency and high level viability (near 60%).  The age and gender of the 
patients did not influence gene transfer efficiency. The average transfection efficiency 
of all samples, middle-age group (donor age<65y), old-age group (donor age>65y), 
female group and male group was 4.32%, 3.85%, 4.52%, 4.14% and 4.38% respectively. 
There was no significant difference between middle-age and old-age groups, as well as 
female and male groups. Of note, the transfection efficiency showed big variation 
among different individuals.  
        Interestingly, two subpopulations in the donors were observed; and in each, the 
transfection efficiency was linearly correlated to the cell percentage in S-phase. 
However, phenotypic characterization based on stem cell markers (CD29, CD44, CD45, 
CD73 and CD105) indicated that the cells of these two subpopulations were not 
significantly different.   
        The delivery of human VEGF165 gene by PEI led to a clinical meaningful level of 
transgene expression (3.49±0.52 pg VEGF/μg total protein), which was significantly 
higher than that of untransfected cells (1.84±0.11 pg VEGF/μg total protein) and naked 
DNA transfected cells (1.94±0.11 pg VEGF/μg total protein).   
        In this study, we investigated for the first time the influence of age and gender of 
donors on the gene transfer efficiency of human bone marrow MSCs mediated by PEI. 
We noticed a big variation of transfection efficiency among different individuals. By 
analyzing the data from multiple patients, we found two subpopulations in the donors 
according to the relationship between transgene expression efficiency and cell 
percentage in S-phase. However, the mechanism for the different behavior of these two 
subpopulations is not clear at present and needs to be further investigated. Finally, our 
result indicated that the expression of therapeutic gene VEGF could be enhanced by PEI 
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to a clinical meaningful level. In summary, this study improved our understanding of 
cationic polymer mediated gene delivery into human MSCs, and demonstrated the 
feasibility to use polymer for genetic modification of stem cells.  Nevertheless, further 
study is still necessary to improve the gene delivery performance of polymer and clarity 
some cellular mechanism.   
 
2. Recruitment of stem cells for cardiac function improvement  
 
        Matrigel is an injectable gelatinous mixture containing ECM components and 
various growth factors. In our study, matrigel was injected intracardiacly after MI in rat 
model, and the restoration of cardiac functions was assessed [Attached article 2]. 
        The intracardiac administration of matrigel could enhance contraction kinetics of 
left ventricle. Compared with MI-PBS (myocardial infarcted, treated with PBS) group, 
MI-M (myocardial infarcted, treated with matrigel) hearts showed 22.7% increase in left 
ventricular ejection fraction (LV-EF), significantly enhanced peak rate of LV pressure 
rise and 24.5% increase in peak rate of LV pressure decline.   
        The intracardiac delivery of matrigel did not reduce infarction size. The infarction 
size of MI-M group (20.98±1.25%) showed no significant reduction compared with MI-
PBS group (21.48±1.49%) 4 weeks after MI. However, the left ventricle wall thickness 
(LWT) of MI-M group (0.72±0.02mm) was significantly higher than that of MI-PBS 
group (0.62±0.02mm), indicating that matrigel could attenuate the decrease of infarct 
wall thickness. Moreover, MI-M hearts presented significantly higher capillary density 
in infarct border zone (130.88±4.7 vessels per HPF) compared with MI-PBS hearts 
(115.40±6.0 vessels per HPF), suggesting that matrigel could promote neoangiogenesis.  
        The local injection of matrigel could improve the recruitment of stem cells to the 
infarcted hearts. The number of CD34+ and CD117+ stem cells in MI-M hearts 
(13.0±1.51 CD34+, 38.3±5.3 CD117+ per HPF) was significantly higher than that in MI-
PBS hearts (5.6±0.67 CD34+, 25.7±1.5 CD117+ per HPF) 4 weeks after MI.  
        In brief, we presented for the first time that intracardiac administration of matrigel 
after MI could increase the local number of CD34+ and CD117+ stem cells. Meanwhile, 
we provided the evidence that the recruited stem cells might promote the cardiac 
regeneration. Despite these encouraging findings, the exact mechanism by which 
matrigel act on stem cells and restore myocardial functions, has not been clearly 
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identified. We supposed that several potential factors might mediate this process. 
However, further study is necessary to confirm or clarify this mechanism.  
 
3. Non-viral delivery of ASO for tumor inhibition 
 
        Differential mRNA splicing and alternative promoter usage of the TP73 gene lead 
to the expression of multiple N-terminally truncated isoforms (ΔEx2, ΔEx2/3, ΔN’, ΔN) 
that act as oncogenes. In our study, the delivery of LNA-ASO with non-viral method 
was performed to suppress tumor cell growth [Attached article 3]. 
        ASO-116, which binds to ΔEx2/3p73 mRNA, was complexed by PEI. In vitro, 
PEI/ASO-116 polyplexes led to 6- to 9-fold decrease of target mRNA level on SK-Mel-
29 cells after transfection. Due to this inhibitory effect on ΔEx2/3p73, PEI/ASO-116 
treated cells showed significantly reduced proliferation rate over 5 days, compared with 
PEI/ASO-sc (scrambled control) treated cells and untreated cells.  
        In vivo, the distribution of PEI/ASO-116 polyplexes in the malignant melanoma 
tumors was investigated using fluorescence-labeled polyplexes. Results indicated that 
the polyplexes distributed within the whole tumor in 1 hour after intratumoral injection. 
Although the concentration of the polyplexes decreased over time in the tumor, a 
fraction still remained detectable after 24 hours, which is sufficient to allow continuous 
availability of polyplexes under daily administration.   
        In order to enhance the antitumoral efficacy, PEI/ASO-116 polyplexes were 
conjugated onto magnetic nanobeads (MNBs) and the MNB/PEI/ASO-116 complexes 
were intratumorally injected in the presence of a magnet implanted near the tumor. 
Magnetic force-restriction could prevent diffusion of the ASO from the injection site. 
As a result, MNB/PEI/ASO-116 complexes significantly reduced the tumor growth rate 
compared with PEI/ASO-116 polyplexes, as indicated by tumor growth curves. 
MNB/PEI/ASO-116 complexes and PEI/ASO-116 polyplexes offered an equally strong 
suppression of ΔEx2/3p73 expression (7-fold and 8.5-fold) compared with control 
group. However, MNB/PEI/ASO-116 complexes induced a more than 2 times higher 
increase of tumor suppressive TAp73. This indicates that enhanced specific therapeutic 
efficacy can be achieved by keeping the ASO concentrated in the tumor via magnetic 
force-restriction.  
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        In summary, our results demonstrated that polymer mediated ASO delivery might 
be utilized for tumor inhibition. Coupled with inorganic MNBs, polymer can improve 
the in vivo administration of ASO and accordingly enhance the antitumoral efficacy. 
The data support the utilization of non-viral gene delivery method for cancer treatments.  
 
4. GAS mediated gene delivery for stem cell recruitment 
 
        Gene activated matrixes have been used effectively in various applications due to 
their capability to allow local and sustained gene release to the desired site. In our study, 
gene activated substrates (GASs) were prepared by mixing PEI/DNA polyplexes with 
substrate materials (human fibronectin or rat tail collagen). The performance of the 
GASs on gene delivery and stem cell recruitment was investigated [Attached article 4&5]. 
        GASs could allow sustained gene release over 2 months. On the first day, about 
37% of total polyplexes was released from gene activated collagen (GAC). After that, 
the release speed slowed down and the cumulative amount of released polyplexes was 
approximately 41% after 67 days. Gene activated human fibronectin (GAH) presented 
more gently gene release. About 3% of polyplexes was released on the first day and up 
to 12% of polyplexes was released in 67 days.  
        GAC allowed high transfection efficiency and low cytotoxicity. At N/P ratio 4 and 
DNA dosage 10.0μg/cm2, the transfection efficiency was 5.8×105 RLU/mg protein, and 
the cell viability was around 75% which was 1.85 times higher than that of substrate-
free control group. GAH could also offer high transfection efficiency (5.6 ×106 RLU/mg 
protein at N/P ratio 4 and DNA dosage 7.5μg/cm2), but no improvement of cell viability 
was observed.  
        Both GAC and GAH could be used for controllable gene transfer in designed area. 
Improtantly, the transfected cells could be used for stem cell recruitment. In vitro, rat 
MSCs transfected by SDF-1α-GAH and African green monkey kidney (COS7) cells 
transfected by SDF-1α-GAC showed the capability to guide the migration and homing 
of CD117+ stem cells. In vivo, the implantation of SDF-1α-GAC into mouse hindlimb 
led to transgene express and consequent CD117+ stem cells homing, whereas the 
induced inflammation significantly diminished in 2 weeks.  
        In this study, we prepared GASs to provide the homing signals that promote stem 
cells migration and recruitment. The GASs hold the advantage of allowing localized 
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gene delivery, sustained gene release, high transfection efficiency and low cytotoxicity. 
They can easily be coated onto the surface of scaffold for implantation. Our GASs 
containing SDF-1α gene induced CD117+ stem cells migration and homing both in vitro 
and in vivo, showing the potential to overcome the limitation of low stem cell amount in 
intrinsic tissue pools for tissue repair. Furthermore, the sustained long-term SDF-1α 
gene expression by GASs might conquer the drawbacks associated with the direct 
administration of SDF-1α protein, since SDF-1α has very short half-life and can be 
inactivated and cleaved in vivo. In summary, the GASs provide a useful tool for stem 
cell based tissue engineering. They can also be used as model systems to study the 
molecular interplay between other adhesion molecules involved in stem cell therapy.  
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Conclusions 
 
        In present dissertation, PEI mediated non-viral gene delivery was studied and 
combined with stem cell-based therapy. We transfected human MSCs with PEI 
mediated gene delivery to study the genetic modification of adult stem cells [Attached article 
1]. We evaluated the therapeutic effect of stem cells on restoration of heart functions 
after myocardial infarction in rat model [Attached article 2]. We delivered antisense 
oligonucleotide (ASO) with non-viral gene transfer method to inhibit tumor growth 
[Attached article 3]. And we developed a novel gene transfer technique called gene activated 
substrate (GAS) which might be used for stem cell recruitment [Attached article 4&5]. Based 
on our experimental results, some conclusions can be drawn as follows: 
1. Human bone marrow derived MSCs could be genetically modified via PEI 
mediated gene delivery. The highest transfection efficiency was achieved at N/P 
ratio 2 and 6.0μg DNA/cm2 culture area, while the cell viability under this 
condition was still at a high level. The donors’ age and gender did not influence 
the gene transfer efficiency. Two subpopulations in the donors were observed; 
and in each, the transfection efficiency was linearly correlated to the cell 
percentage in S-phase. However, there were no phenotypic differences between 
these two subpopulations. The mechanism is still not clear at present and needs 
to be further studied. Finally, therapeutic gene expression was significantly 
enhanced by PEI onto a clinical meaningful level, suggesting the feasibility to 
use polymer for genetic modification of stem cells.   
2. The recruitment of CD34+ and CD117+ stem cells might improve the restoration 
of heart functions after MI in rat model. After the delivery of Matrigel into 
myocardium by intracardiac injection following MI, the LV function, the infarct 
wall thickness of left ventricle and the capillary density of the hearts were 
significantly improved. The number of CD34+ and CD117+ stem cells was 
significantly increased in the Matrigel treated hearts. We assumed that the 
restoration of myocardial functions might attribute to the recruitment of stem 
cells. 
3. Non-viral gene delivery could be applied to transfer not only DNA, but also 
other genetic materials. By delivering ASO with non-viral method, the tumor 
cell growth could be effectively inhibited both in vitro and in vivo. The 
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utilization of magnetic nanobeads (MNBs), onto which PEI/ASO polyplexes 
were conjugated, could improve the ASO transfer efficiency and thereby 
enhance the antitumoral efficacy.  
4. Gene activated substrate (GAS) may allow localized gene delivery, sustained 
gene release, high transfection efficiency and low cytotoxicity. It could be easily 
coated onto scaffold for implantation. When SDF-1α gene was utilized, GAS 
could induce CD117+ stem cell migration and homing both in vitro and in vivo. 
Thus, GAS shows high potential to recruit stem cells for regenerative therapy. 
As for the substrate materials, collagen was more suitable than fibronectin since 
collagen allowed higher cell viability.  
5. Although presenting relative excellent performance for both in vitro and in vivo 
gene delivery, PEI showed some intrinsic drawbacks. The relative high 
cytotoxicity and non-biodegradability are the crucial ones. In order to achieve 
improved therapeutic effects, the transfection efficiency of PEI needs to be 
increased. Further improvements might focus on several directions. First is the 
chemical modification or conjugation to increase site-specificity, decrease 
cytotoxicity and enhance gene transfer efficiency. Second is the crosslinking of 
LMW-PEI via biodegradable bonds or polymers to provide biodegradability and 
reduce toxicity. Third is the synthesis of novel polymers that have the similar 
amines ratio (primary amine: secondary amine: tertiary amine) like PEI to allow 
high buffering capability.    
        In summary, this dissertation provides novel scientific-meaningful information 
regarding non-viral gene delivery and stem cell-based therapy. Further investigations in 
the fields of gene therapy and stem cell therapy need to be performed. It is senseful to 
consider the combination of these two therapeutic strategies, since it shows the potential 
to largely increase the therapeutic effects.   
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